It has long been known that bacterial pathogens are becoming increasingly resistant to antibiotics. However, common medications are also becoming less effective against malaria, a tropical disease caused by a parasite. To counteract this development, a research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH), has now developed a new drug candidate that can kill the malaria pathogen even when existing drugs are no longer effective. The team has now published its findings in the journal Angewandte Chemie.

Researchers at the Icahn School of Medicine at Mount Sinai and their collaborators have developed a new technology to track beneficial bacteria after fecal microbiota transplants (FMT). The approach provides a detailed view of how donor microbes take hold and persist in the patients’ gut—not only which bacteria successfully colonized but how they change over time. These insights may guide the design of safer and more effective microbiome-based therapies. The study was published in the October 22 online issue of Nature Microbiology [DOI: https://doi.org/10.1038/s41564-025-02164-8].

A new study in dogs—an ideal model for this research because they share our genetic diversity, diseases, and home environments—has uncovered molecular clues that could shed light on how aging unfolds in pets and people alike.